Controversies

Debate-style presentations on challenging issues in dermatology. (Number of sessions: 11)
 
Note: The position each speaker represents may not necessarily be his/her own professional viewpoint.
 

Tuesday June 9

09:00 – 10:30

CN01 Toxic Epidermal Necrolysis – To Treat or Not To Treat? Immunotherapy Versus Supportive Therapy
Chair: Abdul-Ghani Kibbi (Lebanon)
 
Speaker: Pierre Wolkenstein (France)
Position: Immunotherapy
 
Speaker: Jean-ClaudeRoujeau (France)
Position: Supportive Therapy

 
14:00 – 15:30

CN02 Psoriasis: Is Almost Everyone Treatable with Biologics?
Chair: Hamangi Jerajani (India)
 
Speaker: Luigi Naldi (Italy)
Position: Not everyone Is treatable with biologics
 
Speaker: Craig Leonardi (United States)
Position: Everyone is treatable with biologics

 

15:30 – 17:00

CN03 Mohs Micrographic Surgery for Nonmelanoma Skin Cancer – Does Every Facial Tumor Really Need It?
Chair: Mary Maloney (United States)
 
Speaker: John Carucci (United States)
Position: Every facial tumor needs Mohs surgery
 
Speakers: Michael Bigby (United States) and Brett Coldiron (United States)
Position: It is not necessary for every facial tumor to receive Mohs surgery

 

Wednesday June 10

09:00 – 10:30

CN04 Is There Now Enough Evidence That Controlling Psoriasis Really Decreases Cardiovascular Risk?
Chair: Xuejun Zhang (China)
 
Speaker: Thomas Luger (Germany)
Position: Yes there is enough evidence
 
Speakers: Robert Stern (United States) and Tamar Nijsten (Netherlands)
Position: No, there is not enough evidence

 

CN05 Moderate to Severe Bullous Pemphigoid – Total Body Topical Therapy Versus Systemic Agents
Chair: Wolfram Sterry (Germany)
 
Speaker: Pascal Joly (France)
Position: Total body topical therapy
 
Speaker: Branka Marinovic (Croatia)
Position: Systemic agents

 

Thursday June 11

09:00 – 10:30

CN06 Is There Any Future for PUVA Therapy?
Chair: Chung-Hong Hu (Chinese Taipei)
 
Speakers: Herbert Hönigsmann (Austria) and Berhard Ortel (United States)
Position: Yes, there is a future
 
Speaker: James Ferguson (United Kingdom)
Position: No, there is no future

 

CN07 Laboratory Testing for Chronic Urticaria – Minimal Versus Extensive
Chair: Hee Chul Eun (Korea)
 
Speaker: Nicholas Soter (United States)
Position: Minimal testing
 
Speakers: Torsten Zuberbier (Germany) and Kiran Godse (India)
Position: Extensive testing

 

Friday June 12

09:00 – 10:30

CN08 Patient Care is Enhanced When Dermatologists Routinely Follow Guidelines of Care. Pro or Con?
Chair: Marcia Ramos e Silva (Brazil)
 
Speaker: Alexander Nast (Germany)
Position: Guidelines should be routinely followed
 
Speakers: Stephen Stone (United States) and Lucinda Buescher (United States)
Position: Routinely following guidelines does not enhance patient care

 

CN09 Actinic Keratoses – Is Routine Eradication Necessary?
Chair: Jorge Ocampo (Mexico)
 
Speaker: Neal Bhatia (United States)
Position: Routine eradication is necessary
 
Speaker: Clay Cockerell (United States)
Position: Routine eradication is unnecessary

 

Saturday June 13

09:00 – 10:30

CN10 The Cutaneous Melanoma Epidemic – Is it Real or an Artifact of Aggressive Diagnosis?
Chair: Francisco Camacho (Spain)
 
Speaker: Earl Glusac (United States)
Position: The melanoma epidemic is mostly due to aggressive
 
Speakers: Jason Rivers (Canada) and Darrell Rigel (United States)
Position: The melanoma epidemic is real

 

14:00 – 15:30

CN11 Global Dermatology in  2025 – Innovative Expensive Treatments for a Few Versus Low-cost Medications for Everyone?
Chair: Christopher Griffiths (United Kingdom)
 
Speakers: Warren Piette (United States) and Joerg Albrecht (United States)
Position: Low cost medications for everyone have the greatest impact on our patients
 
Speaker: Bruce Strober (United States)
Position: Innovative treatments enhance dermatology and are temporarily expensive